This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2009 May;145(3):333.

doi: 10.1111/j.1365-2141.2009.07616.x. Epub 2009 Feb 13.

Where now in elderly AML?

PMID: 19222475
DOI: 10.1111/j.1365-2141.2009.07616.x

Editorial

Where now in elderly AML?

Chris Bunce. Br J Haematol. 2009 May.

. 2009 May;145(3):333.

doi: 10.1111/j.1365-2141.2009.07616.x. Epub 2009 Feb 13.

Author

PMID: 19222475
DOI: 10.1111/j.1365-2141.2009.07616.x

No abstract available

PubMed Disclaimer

Comment on

The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome: the results of the LRF AML14 trial.
Burnett AK, Milligan D, Goldstone A, Prentice A, McMullin MF, Dennis M, Sellwood E, Pallis M, Russell N, Hills RK, Wheatley K; United Kingdom National Cancer Research Institute Haematological Oncology Study Group. Burnett AK, et al. Br J Haematol. 2009 May;145(3):318-32. doi: 10.1111/j.1365-2141.2009.07604.x. Epub 2009 Mar 8. Br J Haematol. 2009. PMID: 19291085 Clinical Trial.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Wiley
Medical
- MedlinePlus Health Information